Events Partner Content CRISPR & Precision Gene Editing Congress - Berlin 2017 CRISPR & Precision Gene Editing Congress Berlin 2017
News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
News China to begin first in-human CRISPR trial next month Phase 1 trial will investigate safety and tolerability in non-small cell lung cancer.
News Fulcrum Therapeutics promises new drugs for rare disorders Company launched following $55 million series A funding round.
News Agenovir secures funding for CRISPR antiviral therapies Antiviral therapy specialist Agenovir has secured $10.6 million in funding from a series A funding round.
News Caribou gains $30m funding for CRISPR-Cas platform Genetic engineering specialist Caribou Biosciences has secured $30 million in a series B funding round.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
